Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2025-12-25 @ 2:22 AM
NCT ID:
NCT04192734
Eligibility Criteria:
Inclusion Criteria:
1. Age ≥19 years at the time of study registration
2. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma
3. Locally advanced unresectable or metastatic disease
4. Patients who have received previous palliative first-line systemic therapy including fluoropyrimidine and platinum for advanced gastric or gastroesophageal junction adenocarcinoma
5. Patients who have received ramucirumab plus paclitaxel combination therapy between May 2018 and December 2018 under the Korea National Health Insurance System
Exclusion Criteria:
1. Patients who have received ramucirumab plus paclitaxel combination therapy outside of the Korea National Health Insurance System
2. Patients who have received ramucirumab monotherapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
19 Years
Study:
NCT04192734
Study Brief:
Protocol Section:
NCT04192734